Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Financing Activities (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Cash from Financing Activities for 7 consecutive years, with $7.9 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 36.84% to $7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.2 million through Dec 2025, down 74.15% year-over-year, with the annual reading at $30.2 million for FY2025, 74.15% down from the prior year.
  • Cash from Financing Activities hit $7.9 million in Q4 2025 for Allogene Therapeutics, up from $3.2 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $108.6 million in Q2 2024 to a low of $24000.0 in Q2 2022.
  • Historically, Cash from Financing Activities has averaged $12.9 million across 5 years, with a median of $2.8 million in 2021.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 99.46% in 2021 and later soared 372916.67% in 2023.
  • Year by year, Cash from Financing Activities stood at $322000.0 in 2021, then plummeted by 85.71% to $46000.0 in 2022, then skyrocketed by 236.96% to $155000.0 in 2023, then soared by 3605.16% to $5.7 million in 2024, then surged by 36.84% to $7.9 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ALLO at $7.9 million in Q4 2025, $3.2 million in Q3 2025, and $5.1 million in Q2 2025.